1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Patience Needed On US Biosimilars, Says Samsung Bioepis’ Ko

Expectations For US Biosimilars ‘May Have Been Excessive’

 
• By Dave Wallace

In the first part of an exclusive interview with Generics Bulletin, Samsung Bioepis CEO Christopher Hansung Ko sets out his views on the US biosimilar market.

Hourglass
The US biosimilars market will take time to mature, Ko insists • Source: Shutterstock

As CEO of the Samsung Bioepis joint venture between Samsung BioLogics and Biogen, Christopher Hansung Ko oversees a major player in the global biosimilars arena that can boast substantial interests and experience in the US market, as well as a wealth of experience in Europe and a foot in the door of major Asian and Latin American markets like China and Brazil. 

In the first part of an exclusive interview with Generics Bulletin, Ko highlighted the need for stakeholders to adopt a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Xbrane Sets Date For Latest Run At Ranibizumab In US

 
• By Dave Wallace

After a series of setbacks for its Lucentis (ranibizumab) biosimilar filing in the US, Xbrane Biopharma now has a fresh action date from the FDA – although any approval will be contingent on a successful agency reinspection of its manufacturing sites.

Zydus Strikes Landmark $141m Agreement To Break Into Global CDMO Business

 
• By Dean Rudge

Zydus Lifesciences said it would be able to leverage supply chain dynamics and a “favorable geopolitical environment” to expand its reach in the US and globally as it penned a trio of agreements to plant its flag in the global CDMO space.

Dr Reddy’s And Alvotech Team Up On Keytruda Rival

 
• By Dave Wallace

After previously partnering on denosumab, Alvotech and Dr Reddy’s have announced a further alliance to co-develop a biosimilar version of Keytruda (pembrolizumab).

Glenmark Adamant FDA Monroe Site Reinspection Could Happen ‘Any Time’

 
• By Dean Rudge

A weak second half in Glenmark’s India business during the firm’s 2025 financial year took the gloss off its earnings somewhat for the year. However, Glenmark is plotting several avenues to return to growth, in both of its core business regions: India and the US.

More from Business